• Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
  • Favorable safety profile observed to date, with limited hematological toxicity
  • Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need